|
|
Neurology December 2008
Volume 71
Issue 23
| Editorial |
recent advances and current clinical perspectives in the diagnosis and treatment of glycogenosis type ii.
- Angelini, Corrado. Pages: S1-S2
|
| Introduction |
objectives and methods of the supplement.
- Danesino, Cesare. Pages: S3
|
| Articles |
diagnosis of glycogenosis type ii.
- Bembi, B, Cerini, E, Danesino, C, Donati, M, Gasperini, S, Morandi, L, Musumeci, O, Parenti, G, Ravaglia, S, Seidita, F, Toscano, A, Vianello, A. Pages: S4-S11
>
Show/Hide Abstract
The diagnosis of glycogenosis type II is often complicated by the rarity of the condition and the heterogeneity of the clinical manifestations of the disease. It is a progressive, debilitating, and often fatal neuromuscular disorder that manifests as a continuum of clinical phenotypes, which vary with respect to organ involvement, age at onset, and severity. Early diagnosis requires both increased awareness among physicians regarding the clinical characteristics of the disease and fast and reliable acid alpha-glucosidase (GAA) enzyme activity assays to confirm the GAA deficiency. The clinical diagnosis of glycogenosis type II is confirmed by virtual absence (found in infants) and marked reduced activity (found in juveniles and adults) of GAA enzyme in blood samples, cultured fibroblasts, and muscle biopsies. This article specifically highlights the need for early recognition of the clinical manifestation of the disease in infants, juveniles, and adults. Descriptions of the main clinical features of the condition, as well as differential diagnosis are included. In addition, the tests required for a confirmed diagnosis are described, and use of muscle imaging to evaluate muscle pathology is reviewed.(C)2008AAN Enterprises, Inc.
|
management and treatment of glycogenosis type ii.
- Bembi, B, Cerini, E, Danesino, C, Donati, M, Gasperini, S, Morandi, L, Musumeci, O, Parenti, G, Ravaglia, S, Seidita, F, Toscano, A, Vianello, A. Pages: S12-S36
>
Show/Hide Abstract
Glycogenosis type II is a multisystem disorder that requires management by a multidisciplinary team. The team should include several specialists, such as a metabolic disease specialist or biochemical geneticist, cardiologist, pulmonologist, neurologist, neuromuscular specialist, intensivist, orthopedist, respiratory therapist, physical therapist, occupational therapist, otolaryngologist speech therapist, audiologist, genetic counselor, and a metabolic dietician, who, as a team, will be capable of addressing the different manifestations of the condition. Aspects of functional assessment, rehabilitation, nutritional management, care coordination, nursing, genetic counseling, prenatal diagnosis, and screening are discussed in this article. In addition, treatment of glycogenosis type II is reviewed with attention to emerging therapeutic options.(C)2008AAN Enterprises, Inc.
|
|
Advertisement
|
